Search company, investor...

Executives

11

Board of Directors

3

Zogenix Management Team

11 Team Members

Zogenix has 11 executives. Zogenix's current Chief Executive Officer is Roger L Hawley.

Name

Work History

Title

Status

Roger L Hawley

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Roger L Hawley

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Zogenix Board of Directors

3 Board of directors

Zogenix has 3 board of directors, including Alex Zisson.

Name

Firm

Work History

Other Seats

Alex Zisson

Alex joined Thomas, McNerney & Partners in 2002 and is currently a board member of Clarus Therapeutics, Tranzyme Pharma , Quinnova Pharmaceuticals and Zogenix. Before joining the firm, he spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan H&Q). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceutical, large-cap pharmaceutical, drug delivery and diagnostic industries. He was the lead analyst on 10 book-running IPOs and 20 book-run secondary offerings, raising over $2 billion for health care companies. In 1997, Alex was named a Managing Director and began assuming management responsibilities for the health care research group and the firm's annual January conference. After the merger of Chase H&Q and JPMorgan, he became the firm's Health Care Strategist. Alex was named twice in The Wall Street Journal's All-Star Analysts Survey, including during his last year at JPMorgan when he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and 'home run' hitting (#8 across all industries). He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.

Zogenix

James Blair

Jim has been a partner of the venture capital firm Domain and Associates since the firm’s founding in 1985. Jim has more than 40 years of experience with venture and emerging growth companies. He has been involved in the creation and successful development at the board level of more than 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Cadence Pharmaceuticals, Dura Pharmaceuticals, GeneOhm Sciences, and Molecular Dynamics.

Zogenix

Kurt Wheeler

Zogenix

Name

Alex Zisson

James Blair

Kurt Wheeler

Firm

Work History

Alex joined Thomas, McNerney & Partners in 2002 and is currently a board member of Clarus Therapeutics, Tranzyme Pharma , Quinnova Pharmaceuticals and Zogenix. Before joining the firm, he spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan H&Q). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceutical, large-cap pharmaceutical, drug delivery and diagnostic industries. He was the lead analyst on 10 book-running IPOs and 20 book-run secondary offerings, raising over $2 billion for health care companies. In 1997, Alex was named a Managing Director and began assuming management responsibilities for the health care research group and the firm's annual January conference. After the merger of Chase H&Q and JPMorgan, he became the firm's Health Care Strategist. Alex was named twice in The Wall Street Journal's All-Star Analysts Survey, including during his last year at JPMorgan when he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and 'home run' hitting (#8 across all industries). He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.

Jim has been a partner of the venture capital firm Domain and Associates since the firm’s founding in 1985. Jim has more than 40 years of experience with venture and emerging growth companies. He has been involved in the creation and successful development at the board level of more than 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Cadence Pharmaceuticals, Dura Pharmaceuticals, GeneOhm Sciences, and Molecular Dynamics.

Other Seats

Zogenix

Zogenix

Zogenix

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Zogenix to Competitors

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

E
Emagin Therapeutics

Emagin Therapeutics develops new and improved drug entities to treat acute, chronic and cancer-related pain and delivery systems for pain management.

N
NaryxPharma

Naryx Pharma is focused on development of its product candidates of inhaled, nebulized, intranasal drug formulations.

Orexo Logo
Orexo

Orexo is a pharmaceutical company that focuses on the development of improved pharmaceuticals. The company's main offerings include innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Orexo primarily sells to the healthcare industry. It is based in Uppsala, Sweden.

Q
Quark Pharmaceuticals

Quark Pharmaceuticals is a development-stage pharmaceutical company discovering and developing RNA interference (RNAi)-based therapeutics.

U
Urigen Pharmacueticals

Urigen Pharmaceuticals focuses on the development and commercialization of innovative products for urological indications within the healthcare sector. The company specializes in creating treatments aimed at alleviating the causes and symptoms of urological ailments, particularly Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). It is based in North Brunswick, New Jersey.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.